Ventavis® (Iloprost): Evaluation of Inhaled Iloprost Effects Using the Breelib™ Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

Trial Profile

Ventavis® (Iloprost): Evaluation of Inhaled Iloprost Effects Using the Breelib™ Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Iloprost (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms VENTASTEP
  • Sponsors Bayer
  • Most Recent Events

    • 05 Mar 2018 Planned End Date changed from 31 Mar 2019 to 31 Jul 2019.
    • 05 Mar 2018 Planned primary completion date changed from 15 Jan 2019 to 31 Jan 2019.
    • 05 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top